Last reviewed · How we verify
NCT04119154: Chedza
Feasibility and Accuracy of Nanosensor-based Cancer Diagnosis at the Point-of-care (Chedza)
NA trial testing Contrast Microhalography (CEM) in Breast Neoplasms in 270 participants. Completed in 20 September 2021.
20 September 2021
Quick facts
| Lead sponsor | Harvard School of Public Health (HSPH) |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | diagnostic |
| Enrollment | 270 |
| Start date | 1 August 2019 |
| Primary completion | 20 September 2021 |
| Estimated completion | 20 September 2021 |
| Sites | 1 location across Botswana |
Drugs / interventions tested
- Contrast Microhalography (CEM)
Conditions studied
- Breast Neoplasms — all drugs for Breast Neoplasms →
- Lymphoma — all drugs for Lymphoma →
Sponsor
Harvard School of Public Health (HSPH)
Who can join
18 and older, any sex, with Breast Neoplasms or Lymphoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Prospective feasibility and validation study of a novel, near-to-care modality for diagnosis of malignancy among cancer suspects.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04119154
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Breast Neoplasms
Currently open trials in the same condition.
- NCT07214532 — Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer · NA · recruiting
- NCT07500428 — Construction of a Benchmark for Breast Ultrasound AI Interpretation and Performance Evaluation of Multimodal AI Models · recruiting
- NCT07581834 — Efficacy and Safety of Dalpiciclib Combined With Endocrine Adjuvant Therapy for Early HR +/HER2- Breast Cancer: a Multic · Phase 2 · recruiting
- NCT07222215 — PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA) · Phase 2 · recruiting
- NCT07465393 — Facility-Based Multi-Modal Rehab vs. Home-Based Resistance Exercise for Quality of Life in Breast Cancer Survivors · NA · recruiting
Other Harvard School of Public Health (HSPH) trials
Trials by the same sponsor.
- NCT07493772 — Multiple Micronutrient Supplementation With Digital Layering Among Adolescents in Tanzania · NA · not yet recruiting
- NCT06982339 — Beat the Heat Boston · NA · recruiting
- NCT06765863 — LIFT-UP: Randomized Controlled Trial of Fortification of Human Milk · NA · recruiting
- NCT06102044 — Zinc Supplementation for Young Infants With Clinical Severe Infection in Tanzania · Phase 3 · recruiting
- NCT06390943 — Low Birthweight and Preterm Infant Feeding Trial and Supportive Care Package: Implementation Research · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04119154 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Harvard School of Public Health (HSPH)
- Last refreshed: 2 May 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04119154.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing